The Transthyretin Amyloid Cardiomyopathy Treatment Market is estimated to be valued at US$ 1687.23 Mn in 2023 and is expected to exhibit a CAGR of 31.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Transthyretin Amyloid Cardiomyopathy is caused due to deposition of abnormal transthyretin protein in heart muscles. Main symptoms includes shortness of breath, irregular heartbeat. Currently approved treatments includes tafamidis and diflunisal which helps in stabilization of normal transthyretin thus reducing amyloid deposits. Novel gene therapy and antisense oligonucleotide approaches are under development which directly target pathogenic transthyretin production showing promising results in clinical trials.
Market Dynamics:
Increasing research funding for rare diseases is a key driver for this market. For instance, National Institutes of Health provides funding support through various grants for research on new treatments for rare heart conditions like transthyretin amyloid cardiomyopathy. Additionally, orphan drug designation and market exclusivity provided by regulatory authorities on approval of drugs for rare diseases incentivizes pharmaceutical companies to invest and develop novel therapies for this market. RNA interference based drugs are gaining significant attention for treatment of transthyretin amyloidosis. Drugs like patisiran and inotersen received FDA approval for hereditary transthyretin-mediated amyloidosis with polyneuropathy in 2018. These novel treatment approaches are anticipated to revolutionize the management of transthyretin amyloid cardiomyopathy over the forecast period.
Segment Analysis
The Transthyretin Amyloid Cardiomyopathy Treatment market is dominated by the drugs sub segment. Medications that slow or halt the progression of ATTR-CM like Pfizer’s Vyndaqel and tafamidis account for over 80% of the market share as these are the only FDA approved drugs for the treatment of the disease.
PEST Analysis
Political: Governments across the globe are supporting initiatives to spread awareness about ATTR-CM and rare diseases through funding of relevant nonprofit foundations.
Economic: The rising aging population globally susceptible to age related conditions like ATTR-CM is contributing to the economic growth of the ATTR-CM treatment market.
Social: Increased adoption of orphan drugs and positive patient outcomes have boosted social acceptance for novel therapeutics targeting rare conditions.
Technological: Advancements in gene therapy and RNA interference mechanisms are accelerating drug development for hereditary forms of ATTR-CM.
Key Takeaways
The Global Transthyretin Amyloid Cardiomyopathy Treatment Market Size is expected to witness high growth, exhibiting CAGR of 31.% over the forecast period, due to increasing research and development activities for drugs targeting both hereditary and wild-type ATTR-CM subtypes.
North America is expected to dominate the Transthyretin Amyloid Cardiomyopathy Treatment market owing to presence of majority of key pharmaceutical companies and approval of first drugs for ATTR-CM in the region. The market in Asia Pacific is anticipated to grow at the fastest pace during the forecast period due to rising geriatric population, increasing healthcare expenditure and growing awareness.
Key players operating in the Transthyretin Amyloid Cardiomyopathy Treatment market are Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc. Major players are focusing on developing advanced gene therapy and RNAi based treatment options with enhanced efficacy and safety profiles.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
